RxDoctor Payments Data

Scottie Withers

Family · Winchester, VANPI 1245902220

Payments from drug & device makers

$10,103in general payments, 2019–2025

Across 565 payments — averaging $17.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Biogen$782
  • AstraZeneca$625
  • SK Life Science, Inc.$594
  • Jazz Pharmaceuticals Inc.$589
  • Lilly USA, LLC$567
  • plus $6K from 49 others

What the payments were for

  • Food & beverage$9,93298%
  • Education$1712%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,103 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$50,994
Medicare patients
233
Services billed
2,039

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VumerityDiroximel Fumarate21$199,629
XywavSodium,calcium,mag,pot Oxybate12$197,818
FingolimodFingolimod Hcl50$142,409
IngrezzaValbenazine Tosylate11$92,737
Nurtec OdtRimegepant Sulfate24$68,355
Emgality PenGalcanezumab-Gnlm40$43,167
QuliptaAtogepant18$19,202
MyrbetriqMirabegron17$11,731
Carbamazepine ErCarbamazepine40$4,918
Dalfampridine ErDalfampridine24$3,646
Gabapentin156$1,812
Carbidopa-LevodopaCarbidopa/Levodopa73$1,736
Dimethyl Fumarate13$1,415
Nortriptyline Hcl104$1,342
Memantine Hcl27$1,165

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$782$199,62921 claims
Neurocrine Biosciences, Inc.Ingrezza$210$92,73711 claims
PfizerNurtec Odt$461$68,35524 claims
AbbVieQulipta$1,232$19,20218 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$114$88211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.

Other family in Winchester

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →